This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Hematology				
Hemolytic uremic syndrome	Golgi integral membrane protein 4 (GOLIM4; GPP130)	<i>In vitro</i> and mouse studies suggest GPP130 inhibitors or Mn ²⁺ could help prevent Shiga toxin-induced hemolytic uremic syndrome. In cultured cells exposed to Shiga toxin, Mn ²⁺ protected cells from cytotoxicity compared with no treatment. In a mouse model of Shiga toxin exposure, daily Mn ²⁺ protected all mice from lethal toxin doses, whereas mice given no treatment died. Next steps include identifying the optimal dose and mode of delivery in mice and testing in combination with antibiotics.	Patent application filed; licensing status unknown	Mukhopadhyay, S. & Linstedt, A.D. <i>Science</i> ; published online Jan. 20, 2012; doi:10.1126/science.1215930 Contact: Adam D. Linstedt, Carnegie Mellon University, Pittsburgh, Pa. e-mail: linstedt@andrew.cmu.edu
SciBX 5(4); doi:10.1038/scibx.2012.98 Published online Jan. 26, 2012				